Matches in UGent Biblio for { <https://biblio.ugent.be/publication/1143723#aggregation> ?p ?o. }
Showing items 1 to 50 of
50
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B191149.
- aggregation creator B191150.
- aggregation creator B191151.
- aggregation creator B191152.
- aggregation creator B191153.
- aggregation creator B191154.
- aggregation creator B191155.
- aggregation creator B191156.
- aggregation creator B191157.
- aggregation creator B191158.
- aggregation creator B191159.
- aggregation creator B191160.
- aggregation creator B191161.
- aggregation creator B191162.
- aggregation creator B191163.
- aggregation creator B191164.
- aggregation creator B191165.
- aggregation creator B191166.
- aggregation creator person.
- aggregation date "2010".
- aggregation format "application/pdf".
- aggregation hasFormat 1143723.bibtex.
- aggregation hasFormat 1143723.csv.
- aggregation hasFormat 1143723.dc.
- aggregation hasFormat 1143723.didl.
- aggregation hasFormat 1143723.doc.
- aggregation hasFormat 1143723.json.
- aggregation hasFormat 1143723.mets.
- aggregation hasFormat 1143723.mods.
- aggregation hasFormat 1143723.rdf.
- aggregation hasFormat 1143723.ris.
- aggregation hasFormat 1143723.txt.
- aggregation hasFormat 1143723.xls.
- aggregation hasFormat 1143723.yaml.
- aggregation isPartOf urn:issn:0732-183X.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the european HR-NBL1/SIOPEN study".
- aggregation abstract "Purpose To reduce the incidence of febrile neutropenia during rapid COJEC (cisplatin, vincristine, carboplatin, etoposide, and cyclophosphamide given in a rapid delivery schedule) induction. In the High- Risk Neuroblastoma- 1 (HR-NBL1) trial, the International Society of Paediatric Oncology European Neuroblastoma Group (SIOPEN) randomly assigned patients to primary prophylactic (PP) versus symptom-triggered granulocyte colony-stimulating factor (GCSF; filgrastim). Patients and Methods From May 2002 to November 2005, 239 patients in 16 countries were randomly assigned to receive or not receive PPGCSF. There were 144 boys with a median age of 3.1 years (range, 1 to 17 years) of whom 217 had International Neuroblastoma Staging System (INSS) stage 4 and 22 had stage 2 or 3 MYCN-amplified disease. The prophylactic arm received a single daily dose of 5 mu g/kg GCSF, starting after each of the eight COJEC chemotherapy cycles and stopping 24 hours before the next cycle. Chemotherapy was administered every 10 days regardless of hematologic recovery, provided that infection was controlled. Results The PPGCSF arm had significantly fewer febrile neutropenic episodes (P = .002), days with fever (P = .004), hospital days (P = .017), and antibiotic days (P = .001). Reported Common Toxicity Criteria (CTC) graded toxicity was also significantly reduced: infections per cycle (P = .002), fever (P = .001), severe leucopenia (P = .001), neutropenia (P = .001), mucositis (P = .002), nausea/vomiting (P = .045), and constipation (P = .008). Severe weight loss was reduced significantly by 50% (P = .013). Protocol compliance with the rapid induction schedule was also significantly better in the PPGCSF arm shown by shorter time to completion (P = .005). PPGCSF did not adversely affect response rates or success of peripheral-blood stem-cell harvest. Conclusion Following these results, PPG-GSF was advised for all patients on rapid COJEC induction.".
- aggregation authorList BK450421.
- aggregation endPage "3524".
- aggregation issue "21".
- aggregation startPage "3516".
- aggregation volume "28".
- aggregation aggregates 1150444.
- aggregation isDescribedBy 1143723.
- aggregation similarTo JCO.2009.27.3524.
- aggregation similarTo LU-1143723.